← Eichor
Study identifier: NCT07091734 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

Condition: Lipodystrophy, Partial  ·  Sponsor: University of Michigan

PhasePhase 2
Planned participants32
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of participant's triglycerides through the reduction of caloric intake. Study Hypothesis: \- The clinical use of Tirzepatide in patients with lipodystrophy may lead to favorable outcomes through the reduction of caloric intake.

This description comes directly from the study's public registry record.

Talk to the study team

Adam Neidert, MS  ·  734-615-0539  ·  aneidert@med.umich.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of MichiganAnn Arbor, Michigan, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07091734